Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Syros Pharmaceuticals (NQ: SYRS )

0.2876 +0.0276 (+10.62%)
Streaming Delayed Price Updated: 1:44 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Syros Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Syros Receives Positive Opinion on Orphan Drug Designation from the European Medicines Agency for Tamibarotene for the Treatment of MDS
From Syros Pharmaceuticals
Via Business Wire
Syros to Report Second Quarter 2022 Financial Results on Tuesday, August 9, 2022
From Syros Pharmaceuticals
Via Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Passage Bio (NASDAQ:PASG) shares moved upwards by 7.7% to $2.66 during Friday's after-market session. The market value of their outstanding shares is at $144.4 million. 
Via Benzinga
The Daily Biotech Pulse: AstraZeneca Goes Shopping, TYME Technologies & Syros Pharma Merger, FDA Clears Vertex Pharma's Stem Cell-Based Diabetes Therapy Study
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
TYME Technologies Shares Surge On Merger Agreement With Syros Pharma
Via Benzinga
Syros to Raise Approximately $190 Million Through Merger with TYME Technologies and Concurrent Private Placement
From Syros Pharmaceuticals
Via Business Wire
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Syros Pharmaceuticals
Via Business Wire
Syros Pharmaceuticals Earnings Perspective: Return On Capital Employed
Syros Pharmaceuticals (NASDAQ:SYRS) brought in sales totaling $5.47 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 5.6%, resulting in a loss of $25.15... 
Via Benzinga
Syros to Present at JMP Securities Life Sciences Conference
From Syros Pharmaceuticals
Via Business Wire
Syros Pharmaceuticals: Q1 Earnings Insights
Syros Pharmaceuticals (NASDAQ:SYRS) reported its Q1 earnings results on Monday, May 16, 2022 at 07:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Earnings Scheduled For May 16, 2022
Companies Reporting Before The Bell • AcelRx Pharmaceuticals (NASDAQ:ACRX) is estimated to report quarterly loss at $0.06 per share on revenue of $550.00 thousand. 
Via Benzinga
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Syros Pharmaceuticals
Via Business Wire
10 Biggest Price Target Changes For Tuesday
Citigroup cut the price target on Insulet Corporation (NASDAQ: PODD) from $350 to $310. Insulet shares fell 1.1% to close at $196.91 on Monday. 
Via Benzinga
The Week Ahead In Biotech: Gene & Cell Therapy Conference, Tapering Earnings News, OKYO Pharma IPO And More
Biopharma stocks remained largely unchanged in the week ending May 13, with the defensive nature of the sector coming to its aid. Stocks reacted to the broader market move and earnings news from... 
Via Benzinga
Syros Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides a Corporate Update
From Syros Pharmaceuticals
Via Business Wire
Earnings Preview For Syros Pharmaceuticals
Syros Pharmaceuticals (NASDAQ:SYRS) is set to give its latest quarterly earnings report on Monday, 2022-05-16. Here's what investors need to know before the announcement. Analysts estimate that Syros... 
Via Benzinga
Syros to Report First Quarter 2022 Financial Results on Monday, May 16, 2022
From Syros Pharmaceuticals
Via Business Wire
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Syros Pharmaceuticals
Via Business Wire
66 Biggest Movers From Yesterday
Gainers Better Therapeutics, Inc. (NASDAQ: BTTX) shares surged 120.4% to close at $2.01 on Monday following a 5% drop on Friday. SoundHound AI, Inc. (NASDAQ: SOUN) shares surged... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
60 Biggest Movers From Yesterday
Gainers Nkarta, Inc. (NASDAQ: NKTX) shares climbed 140.9% to close at $18.72 on Monday after the company announced Phase 1 data from independent dose finding studies of its two... 
Via Benzinga
Syros' CDK12 Inhibitor Shows Anti Tumor Activity In Preclinical Studies
Syros Pharmaceuticals Inc (NASDAQ: SYRS)  
Via Benzinga
Syros Presents New Preclinical Data on its CDK12 Inhibitor Program at American Association for Cancer Research (AACR) Annual Meeting 2022
From Syros Pharmaceuticals
Via Business Wire
55 Biggest Movers From Friday
Gainers Vallon Pharmaceuticals, Inc. (NASDAQ: VLON) shares jumped 100.9% to close at $2.27 on Friday. Vallon Pharmaceuticals engaged Ladenburg Thalmann & Co Inc to evaluate... 
Via Benzinga
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Syros Pharmaceuticals
Via Business Wire
Syros Pharmaceuticals Earnings Perspective: Return On Capital Employed
According to Benzinga Pro data, during Q4, Syros Pharmaceuticals (NASDAQ:SYRS) posted sales of $7.80 million. Earnings were up 8.51%, but Syros Pharmaceuticals still reported an... 
Via Benzinga
Recap: Syros Pharmaceuticals Q4 Earnings
Syros Pharmaceuticals (NASDAQ:SYRS) reported its Q4 earnings results on Tuesday, March 15, 2022 at 07:30 AM. Here's what investors need to know about the announcement.... 
Via Benzinga
The Daily Biotech Pulse: Biogen, Eisai Amend Aduhelm Agreement; Anaptys Acne Drug Flunks Midstage Study; Merck, AstraZeneca Discontinue Prostate Cancer Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Syros Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
From Syros Pharmaceuticals
Via Business Wire
Earnings Scheduled For March 15, 2022
Companies Reporting Before The Bell • IDEAYA Biosciences (NASDAQ:IDYA) is likely to report quarterly loss at $0.31 per share on revenue of $8.98 million. • Citi... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.